Gujarat Fluorochemicals (GUJFLU)



CMP: ₹ 3640

Target: ₹ 4350(20%)

Target Period: 12 months

June 6, 2025

Fluoropolymers upbeat; EV business shaping up well

About the stock: Gujarat Fluorochemicals started as a refrigerants manufacturer and, thereafter, diversified into other areas like speciality chemicals, fluoropolymers, new fluoropolymers and bulk chemicals.

- FY25 segmental mix: Bulk chemicals ~14%, Fluorochemicals ~26%, Fluoropolymers ~58% and others ~2%
- The company has chalked out plans for EV products business with the incorporation of GFCL EV Products Ltd, a 100% subsidiary of GFL), with a substantial investment plan of ₹ 6000 crore over the next 4-5 years.

Investment Rationale:

- Q4FY25 Growth driven by Fluorochemicals and Fluoropolymers Revenues grew 8% YoY to ₹1225 crore driven by both Fluoropolymers business (up 11% YoY) and Fluorochemicals (up 8% YoY). Bulk Chemicals segment de-grew 9% YoY to ₹161 crore. EBITDA grew 29% YoY and margins stood at 25% (up 401 bps YoY) and GPM witnessed 94 bps improvement YoY to 66.3%. Fluoropolymers (58% of sales)- Prices for fluoropolymer remained stable and growth was primarily driven by volume growth in new fluoropolymers Fluorochemicals (26% of sales)- Overall refrigerant gas prices, mainly R-22, have marginally improved during the quarter and the company anticipates further pick up going forward. Specialty chemicals remained flat during the quarter. Bulk Chemicals ((14% of sales)- Gas leakage incident at the CMS-1 plant in Dahej led to ~15% production loss during the quarter, which impacted performance.
- High end Fluoropolymers, RF gas to lead momentum; EV next— The company has invested heavily in high-grade Fluoropolymers capacity build up over the last few years. This, coupled with exit of some global legacy players is expected to improve the growth prospects of Fluoropolymers in FY25. RF gas sub-segment from Fluoropolymers is also in good stead with the changing RF gas quota dynamics globally and its benefits for trickling down to few players including GFL. Bulk chemicals segment on the other hand is expected to remain muted on account of Chinese dumping and excess capacity built-up. We expect Fluoropolymers and the newly inducted EV products segment to drive growth in the future. Potential for EV products segment remains upbeat as the company has the potential to manufacture ~40% of EV battery components. The traction for this segment is expected from H2FY26. The company remains a compelling bet in the Fluorochemicals space with its quest for high-end and differentiated products.

Rating and Target price

• Our target price is ₹ 4350 based on SoTP valuation.



Particulars									
Particular			Α	mount					
Market cap	(₹ Crore)			40,004					
FY25 Total		2,080							
FY25 Cash 8		1,875							
EV (₹ Crore)	40,209								
52 Week H/	L		488	0/2937					
Equity Capit	tal (₹ Cr	ore)		11.0					
Face Value (₹)									
Shareholding pattern									
(in %)	Jun-24	Sep-24	Dec-24	Mar-25					
Promoter	62.6	62.6	62.6	62.6					

9.6

22.6

9.6

23.0

Price	Cha	rt					
30000	1					6,000	
25000				-	۹. a.	- 5,000	
20000	.m			M	HIV (V	4,000	
15000	المستنتئ	كالمتعمولا		J Lymni		- 3,000	
10000						- 2,000	
5000	-					1,000	
0						→ 0	
	Jun- 22 Jec- 22	Jun-23	Dec-23	Jun-24)ec-24	Jun-25	
-	Nifty 500(_		_	nicals (RHS)	

4.6

10.1

10.7

22.1

Key risks

DIIs

Others

(i) Heavy reliance on Fluoropolymers for overall performance improvement (ii) Weakness in agrochem fluorochemicals spilling beyond FY26.

Research Analyst

Siddhant Khandekar siddhant.khandekar@icicisecurities.com

Shubh Mehta shubh.mehta@icicisecurities.com

Vedant Nilekar vedant.nilekar@icicisecurities.com

Key Financial Su	mmary (Bo	ise Busir	iess – Ex	(- EV)				
Key Financials (₹ Crore)	FY22	FY23	FY24	FY25	3 year CAGR (FY22-25E)	FY26E	FY27E	2 year CAGR (FY25-27E)
Revenues	3953.6	5684.7	4280.8	4737.0	6.2	5380.3	6218.6	14.6
EBITDA	1168.5	1965.3	907.4	1099.0	-2.0	1533.4	1834.5	29.2
EBITDA margins (%)	29.56	34.57	21.20	23.20		28.50	29.50	
Net Profit	775.9	1323.1	435.0	546.0	-11.1	711.5	893.4	27.9
EPS (₹)	70.6	120.4	39.6	49.6		64.7	81.2	
PE (x)	51.5	30.2	92.0	73.3		56.3	44.8	
EV to EBITDA (x)	35.5	21.1	46.4	38.0		27.0	22.3	
RoCE (%)	22.6	31.5	10.8	10.6		11.2	11.8	
ROE (%)	18.2	24.0	7.3	7.5		9.0	10.1	

Source: Company, ICICI Direct Research



Exhibit 1: Valuation Summary

Particulars	FY27E (₹ crore)	Multiple	EV (₹ crore)
Base Business FY27E EBITDA (Ex EV)	1,834.5	18	33021
EV business latest deal value			25000
Holding company Discount			35%
Holding company stake			96%
Attributable Enterprice value from EV business			15600
Total EV			48621
Net Debt			798
Targeted Mcap			47823
No of shares			11
Per share Value			4350

Source: Company, ICICI Direct Research

Q4FY25 Conference call highlights

Fluoropolymers-

- Fluoropolymer segment continued to witness positive impact due to exit of legacy players.
- Management anticipates benefit from high-value product adoption in future.
- Management anticipates 25% growth in the segment.
- Management to spend part of ₹400 crore for capacity addition, rebalancing, debottlenecking in fluoropolymer segment.
- GFL is churning portfolio to go for higher value-added grades of PTFE.
- Volume and prices in FKM are stable.
- In PFA has it has also received approvals for some semiconductor applications.
- Relocation of another legacy player and stopping of production in Europe is likely to provide additional traction.

Fluorochemicals/ Bulk Chemicals-

- GFL saw improvement in R-22 prices during the quarter and further increase is expected as global production quotas reduce.
- Direct sales and blend of R125 also improved due to seasonality with management has positive outlook ahead.
- Management expects margin and volume improvements going forward in FY26.
- Company is evaluating multiple options to initiate the commissioning of R32 plant much ahead of the schedule and expect to commence the commercial sale starting during the second half of FY26.
- Bulk Chemicals segment faced challenges due to an incident at Dahej facility leading to approximately 15% production loss.
- Softening of MDC prices due to new capacity additions have negatively impacted our profitability of Bulk Drugs. Management anticipates
- Company is moving ahead with Phase 2 and Phase 3 capacity expansions planned in FY26 for LiPF6.
- LFP plant have achieved mechanical completion with commissioning and trial production set to begin June/July 25.
- Electrolyte and binder plants are also at advanced stage of customer validation with multiple successful global audits already completed.
- GFL's customer engagement has increased significantly with technical visits and audits from prospective clients in the US, EU, Korea, Japan and India.

Battery Materials (GFCL EV)

- Company in EV segment has long-term projected demands by customers and hence company has built inventory for the same.
- Management anticipates revenue from EV business to start contributing towards the second half of FY26 and ramp up the pie in FY27.
- GFL has planned for capex of ₹1200 crore for EV business.



- Management anticipates much larger growth from US then EU.
- Apart from US and EU company also plans to cater Indian market.

Other Aspects

- GFL have increased production of Fluoropolymers and Vacuum materials to build up the pipeline.
- Management aims to achieve EBITDA of ₹2000 crore in FY26.
- Total saving of power and fuel is expected to be ~₹120-150 crore on annualized basis.

FY25

546.0

355.0

-415.0 -188.0

247.0

545.0

-881.0

-241.0

838.0

158.0

-230.0

766.0

189.0

0.0

31.5

55.0

-981.0 -1,122.0

FY24E

435.0

286.1

-144.0

-34.8

84.1

626.4

-970.6

-10.5

0.0

628.6

-171.5

457.1

102.4

0.0

24.0

31.5

FY26E

974.6

468.5

860.0

-263.1

190.3

2,230.2

-1,596.9

0.0

-1,596.9

0.0

638.1

-212.3

425.9

1,059.2

0.0

55.0

1,114.7

₹ crore

FY27E

1,191.3

552.9

-47.5

-297.8

190.3

1,589.2

-850.0

0.0

-850.0

0.0

0.0

-212.3

-212.3

526.9

0.0

1,114.7

1,641.6

Financial Tables

Exhibit 3: P&L Statement (Base Bus	iness)		₹ crore
Year end March	FY24E	FY25	FY26E	FY27E
Total Operating Income	4,280.8	4,737.0	5,380.3	6,218.6
Growth (%)	-24.7	10.7	13.6	15.6
Raw Material Expenses	1,453.3	1,513.0	1,667.9	1,927.8
Gross Profit	2,827.5	3,224.0	3,712.4	4,290.8
Employee Cost	350.4	433.0	484.2	559.7
Other Operating Expenses	1,569.7	1,692.0	1,694.8	1,896.7
EBITDA	907.4	1,099.0	1,533.4	1,834.5
Growth (%)	-53.8	21.1	39.5	19.6
Other Income	106.9	116.0	100.0	100.0
EBITDA, including OI	1,014.3	1,215.0	1,633.4	1,934.5
Depreciation	286.1	355.0	468.5	552.9
Net Interest Exp.	133.1	147.0	190.3	190.3
Other exceptional items	0.0	0.0	0.0	0.0
PBT	595.1	713.0	974.6	1,191.3
Total Tax	160.1	167.0	263.1	297.8
Tax Rate	26.9%	23.4%	27.0%	25.0%
PAT	435.0	546.0	711.5	893.4
Adj.PAT after Minority interest	435.0	546.0	711.5	893.4
Adj. EPS (₹)	39.6	49.6	64.7	81.2
Shares Outstanding	11.0	11.0	11.0	11.0

Source: Company,	ICICI Direct	t Research

Effects of foreign currency translati

Exhibit 4: Cash flow statement

Year end March

Depreciation

Taxes

Others

Others

Others

₹ crore

FY27E

11.0

FY26E

11.0

PBT & Extraordinary

After other adjustments

(Inc) / Dec in Working Capital

CF from operating activities

CF from investing activities

Proceeds from issue of shares

CF from financing activities

Purchase of Fixed Assets

Borrowings (Net)

Net cash flow

Opening Cash

Closing Cash

Exhibit 5: Balance Sheet		
Year end March	FY24E	FY25
Liabilities		
Share Capital	11.0	11.0

Source: Company, ICICI Direct Research

Share capital	11.0	11.0	11.0	11.0
Reserves	5,925.4	7,242.0	7,931.5	8,802.9
Total Shareholders Funds	5,936.3	7,253.0	7,942.5	8,813.9
Minority Interest	0.0	46.0	46.0	46.0
Long Term Borrowings	462.9	478.0	1,085.1	1,085.1
Net Deferred Tax liability	266.5	240.0	240.0	240.0
Other long term liabilities	11.1	8.0	1,008.0	1,508.0
Long term provisions	54.5	61.0	38.6	44.7
Current Liabilities and Provision	s			
Short term borrowings	1,633.1	1,602.0	1,633.1	1,633.1
Trade Payables	518.9	606.0	884.4	1,022.2
Other Current Liabilities	331.1	290.0	329.4	380.7
Short Term Provisions	19.7	25.0	28.4	32.8
Total Current Liabilities	2,502.8	2,523.0	2,875.3	3,068.8
Total Liabilities	9,234.1	10,609.0	13,235.5	14,806.5
Assets				
Net Block	4,105.6	4,136.0	6,338.4	6,635.4
Capital Work in Progress	1,091.3	1,524.0	450.0	450.0
Intangible assets under devl.	192.4	190.0	190.0	190.0
Goodwill on Consolidation	0.0	0.0	0.0	0.0
Non-current investments	16.1	35.0	35.0	35.0
Deferred tax assets	1.0	6.0	6.0	6.0
Long term loans and advances	0.0	0.0	0.0	0.0
Other Non Current Assets	424.1	435.0	1,261.8	1,457.9
Current Assets, Loans & Advance	es			
Current Investments	0.0	279.0	279.0	279.0
Inventories		1 0 2 0 0	1 4741	1,703.7
THE CHOICES	1,571.3	1,820.0	1,474.1	
Sundry Debtors Cash and Bank	1,571.3 844.6 31.5	1,820.0 1,197.0 55.0	1,474.1 1,031.8 1,114.7	1,192.6 1,641.6

27.3

928.9

3,403.6

25.0

907.0

4,283.0

25.0

1,030.2

4,954.7

9,234.1 10,609.0 13,235.9 14,806.9

25.0

1,190.7

6,032.6

Source: Company.	ICICI	D:	D
Source: Company,	ICICI	Direct	Research

Loans and Advances

Other Current assets

Current Assets

Total Assets

Exhibit 6: Key ratios				
Year end March	FY24E	FY25E	FY26E	FY27E
Per share data (₹)				
Adj. EPS	39.6	47.5	68.1	85.1
Adj. Cash EPS	65.6	81.8	110.0	134.6
BV	540.2	558.1	624.2	707.3
DPS	2.0	2.0	2.0	2.0
Operating Ratios (%)				
Gross Margin (%)	66.0	68.0	69.0	69.0
EBITDA Margin (%)	21.2	24.0	28.5	29.5
PAT Margin (%)	10.2	10.8	13.5	14.7
Debtor Days	72	70	70	70
Inventory Days	134	115	100	100
Creditor Days	44	50	60	60
Cash Conversion Cycle	162	135	110	110
Return Ratios (%)				
Return on Assets (%)	4.7	5.2	6.1	6.7
RoCE (%)	10.8	11.7	13.1	13.5
Core RoIC (%)	7.8	8.9	12.2	13.8
RoE (%)	7.3	8.5	10.9	12.0
Solvency Ratios				
Total Debt / Equity	0.4	0.4	0.4	0.3
Net Debt / EBITDA	2.3	2.3	1.5	1.0
Interest Coverage	5.5	5.3	6.4	7.6
Current Ratio	1.4	1.4	1.4	1.6
Quick Ratio	0.7	0.8	0.9	1.1
Valuation Ratios (x)				
EV/EBITDA	45.3	35.9	26.2	21.8
P/E	89.7	74.7	52.1	41.7
P/B	6.6	6.4	5.7	5.0
EV/Sales	9.6	8.6	7.5	6.4

Source: Company, ICICI Direct Research



RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, Third Floor, Brillanto House, Road No 13, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com



ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA; Shubh Mehta, MBA(Tech); Vedant Nilekar, MBA; Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: 167120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or augrantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agarwal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Bhavesh Soni Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report.